2Azziz R,Carmina E,Dewailly D,et al.Positions statement:cri-teria for defining polycystic ovary syndrome as a predominantly hy-perandrogenic syndrome:an Androgen Excess Society guideline[J].J Clin Endocrinol Metab,2006,91(11):4237-4245.
3Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus WorkshopGroup.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J].FertilSteril,2004,81(1):19-25.
4Chang WY,Knochenhauer ES,Bartolucci AA,et al.Phenotypicspectrum of polycystic ovary syndrome:clinical and biochemicalcharacterization of the three major clinical subgroups[J].FertilSteril,2005,83(6):1717-1723.
6Coffey S, Mason H. The effect of polycystic ovary syndrom on health related quality of life. Gynecol Endocrinol,2003;17(5):379～86.
7Elsenbruch S, Hahn S, Kowalsky D et al. Quality of life psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab,2003;88(12):5801～7.
8Eggers S, Kirchengast S. The polycystic ovary syndrome a medical condition but also an important psychosocial problem. Coll Antropol, 2001; 25(2):673～85.
9Pellieux C, Sauthier T, Domenighetti A et al. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in pprimary cardiomyocytes via NPY Y5 receptors.Proc Natl Acad Sci USA, 2000;97(4):1595～600.
10Thorsell A, Michalkiewicz M, Dumont Y et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA, 2000;97(23):12852～7.
